FindTrial
Sign In

Survival benefit of living-donor liver transplantation in patients with a Model for End-stage Liver Disease over 30 in a region with severe organ shortage

Survival benefit of living donor liver transplantation in patients with high model for end-stage liver disease (MELD) score

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CRIS
Registry ID
KCT0008462
Enrollment
800
Registered
2023-05-23
Start date
2022-09-01
Completion date
Unknown
Last updated
2023-05-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

None listed

Sponsors

Yonsei University Health System, Severance Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Adult Between September 2005 and December 2021, patients with a MELD score >=30 who were on the waiting list for LT at Severance Hospital were retrospectively reviewed.

Exclusion criteria

Exclusion criteria: hepatocellular carcinoma (HCC) with distant metastasis any other malignancy diagnosed within 5 years significant deterioration in health status within 2 days of placement on the waitlist

Design outcomes

Primary

MeasureTime frame
survival rate—

Secondary

MeasureTime frame
duration of post-transplantation hospital stay, rate of re-transplantation, presence of complications, and occurrence of rejection—

Countries

Korea, Republic of

Contacts

Public ContactSeung Hyuk Yim

Yonsei University Health System, Severance Hospital

esaitchk@yuhs.ac+82-2-2228-2100

Outcome results

None listed

Source: CRIS (via WHO ICTRP) · Data processed: Feb 4, 2026